Beatrice Bianchi

Beatrice Bianchi

Auto-generated profile, based on publicly available information

Beatrice Bianchi

Institute of Biochemistry and Molecular Medicine, National Center of Competence in Research NCCR TransCure, University of Bern, Bern, Switzerland

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2016 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
LRLicia Rivoltini
Licia Rivoltini
VCvenezian Chiodoni
venezian Chiodoni
PSPaola Squarcina
Paola Squarcina
MTMonica Tortoreto
Monica Tortoreto
AVAntonello Villa
Antonello Villa
VHVeronica Huber
Veronica Huber
Purpose: Exosomes deliver signals to target cells and could thus be exploited as an innovative therapeutic tool. We investigated the ability of membrane TRAIL-armed exosomes to deliver proapoptotic signals to cancer cells and mediate growth inhibition in different tumor models. Experimental Methods and Results: K562 cells, transduced with lentiviral human membrane TRAIL, were used for the production of TRAIL+ exosomes, which were studied by nanoparticle tracking analysis, cytofluorimetry, immunoelectronmicroscopy, Western blot, and ELISA. In vitro, TRAIL+ exosomes induced more pronounced apoptosis (detected by Annexin V/propidium iodide and activated caspase-3) in TRAIL-death receptor (DR)5+ cells (SUDHL4 lymphoma and INT12 melanoma), with respect to the DR5−DR4+KMS11 multiple myeloma. Intratumor injection of TRAIL+ exosomes, but not mock exosomes, induced growth inhibition of SUDHL4 (68%) and INT12 (51%), and necrosis in KMS11 tumors. After rapid blood clearance, systemically administered TRAIL+ exosomes accumulated in the liver, lungs, and spleen and homed to the tumor site, leading to a significant reduction of tumor growth (58%) in SUDHL4-bearing mice. The treatment of INT12-bearing animals promoted tumor necrosis and a not statistically significant tumor volume reduction. In KMS11-bearing mice, despite massive perivascular necrosis, no significant tumor growth inhibition was detected. Conclusions: TRAIL-armed exosomes can induce apoptosis in cancer cells and control tumor progression in vivo. Therapeutic efficacy was particularly evident in intratumor setting, while depended on tumor model upon systemic administration. Thanks to their ability to deliver multiple signals, exosomes thus represent a promising therapeutic tool in cancer. Clin Cancer Res; 22(14); 3499–512. ©2016 AACR.

9 January 2015 in NMR in Biomedicine
Verified
Journal Article
Closed access
PDF file
LTLaura Turati
Laura Turati
MMMarco Moscatelli
Marco Moscatelli
Alfonso MastropietroAlfonso Mastropietro
Alfonso Mastropietro
NDNicholas Dowell
Nicholas Dowell
IZIleana Zucca
Ileana Zucca
LMLudovico Minati
Ludovico Minati

26 March 2018 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
LOLijo Cherian Ozhathil
Lijo Cherian Ozhathil
CDClémence Delalande
Clémence Delalande
BBBeatrice Bianchi
Beatrice Bianchi
GNGabor Nemeth
Gabor Nemeth
SKSven Kappel
Sven Kappel
HAHugues Abriel
Hugues Abriel
Background and Purpose: TRPM4 is a calcium‐activated non‐selective cation channel expressed in many tissues and implicated in several diseases, and has not yet been validated as a therapeutic target due to the lack of potent and selective inhibitors. We sought to discover a novel series of small‐molecule inhibitors by combining in silico methods and cell‐based screening assay, with sub‐micromolar potency and improved selectivity from previously reported TRPM4 inhibitors.Experimental Approach: Here, we developed a high throughput screening compatible assay to record TRPM4‐mediated Na+ influx in cells using a Na+‐sensitive dye and used this assay to screen a small set of compounds selected by ligand‐based virtual screening using previously known weakly active and non‐selective TRPM4 inhibitors as seed molecules. Conventional electrophysiological methods were used to validate the potency and selectivity of the hit compounds in HEK293 cells overexpressing TRPM4 and in endogenously expressing prostate cancer cell line LNCaP. Chemical chaperone property of compound 5 was studied using Western blots and electrophysiology experiments.Key Results: A series of halogenated anthranilic amides were identified with TRPM4 inhibitory properties with sub‐micromolar potency and adequate selectivity. We also showed for the first time that a naturally occurring variant of TRPM4, which displays loss‐of‐expression and function, is rescued by the most promising compound 5 identified in this study.Conclusions and Implications: The discovery of compound 5, a potent and selective inhibitor of TRPM4 with an additional chemical chaperone feature, revealed new opportunities for studying the role of TRPM4 in human diseases and developing clinical drug candidates.

1 March 2016 in International Journal of Cardiology
Verified
Journal Article
Closed access
XDXavier Daumy
Xavier Daumy
MAMohamed-Yassine Amarouch
Mohamed-Yassine Amarouch
PLPierre Lindenbaum
Pierre Lindenbaum
SBStéphanie Bonnaud
Stéphanie Bonnaud
ECEric Charpentier
Eric Charpentier
JSJean-Jacques Schott
Jean-Jacques Schott

8 March 2018 in Frontiers in Physiology
Verified
Journal Article
Open access
PDF file
BBBeatrice Bianchi
Beatrice Bianchi
LOLijo Cherian Ozhathil
Lijo Cherian Ozhathil
AMArgelia Medeiros-Domingo
Argelia Medeiros-Domingo
MGMichael H. Gollob
Michael H. Gollob
HAHugues Abriel
Hugues Abriel
Transient receptor potential melastatin member 4 (TRPM4), a non-selective cation channel, mediates cell membrane depolarization in immune response, insulin secretion, neurological disorders, and cancer. Pathological variants in TRPM4 gene have been linked to several cardiac phenotypes such as complete heart block (CHB), ventricular tachycardia, and Brugada syndrome (BrS). Despite recent findings regarding the functional implications of TRPM4 in cardiac diseases, the molecular and cellular mechanisms leading to altered conduction are poorly understood. In the present study, we identify and characterize four novel TRPM4 variants found in patients with CHB or ventricular fibrillation. Three of them, p.A101T, p.S1044C and a double variant p.A101T/P1204L, led to a decreased expression and function of the channel. On the contrary, the variant p.Q854R showed an increase in TRPM4 current. Recent evidence indicates that altered degradation rate of mutant proteins represents a pathogenic mechanism underlying genetic diseases. In consequence, protein turnover of WT-TRPM4 and TRPM4 variants overexpressed in HEK293 cells was analyzed using cycloheximide, an inhibitor of protein biosynthesis. Upon addition of cycloheximide, WT-TRPM4 decayed with a half-life of ~20 h, while loss-of-expression variants showed a ~30% increase in degradation rate, with a half-life close to 12 h. Together, the gain-of-expression variant showed a higher stability and a doubled half-life compared to WT-TRPM4. In conclusion, decreased or increased protein expression of several TRPM4 variants linked to cardiac conduction disorders or ventricular arrhythmias were found to be caused by altered TRPM4 half-life compared to the WT form.